Those Regulations were adopted following a lengthy and comprehensive consultation exercise by the IAAF's Expert Working Group in conjunction with the IOC, involving world-leading experts across various fields, along with numerous other stakeholders.
The IAAF is happy to note that the CAS Panel in its interim award specifically found that the IAAF and its experts have 'acted with conspicuous diligence and good faith', seeking 'to create a system of rules that are fair, objective and founded on the best available science', and that those rules 'have been administered in confidence and with care and compassion' (including ensuring that athletes affected have received the medical treatment required to ensure their wellbeing). The CAS Panel said this was 'a testament to the seriousness with which the IAAF takes its responsibilities as the global regulator of the sport'.
The IAAF is also happy to note the CAS Panel's ruling that there is a sound scientific basis to the Regulations, in that endogenous testosterone is 'the best indicator of performance differences between male and female athletes', and its acceptance that hyperandrogenic female athletes may have a competitive advantage over athletes with testosterone levels in the normal female range.
However, the IAAF also notes the CAS Panel's view that more evidence is required as to the precise degree of performance advantage that hyperandrogenic female athletes enjoy over athletes with normal testosterone levels, and its directive that the Regulations should be suspended for two years while that evidence is gathered.
The IAAF will now meet as soon as possible with its experts and with the IOC and its experts to discuss how best to address this interim ruling by the CAS. The IAAF will make no further comments on this subject until those discussions are concluded